- Reviews the interplay of the glutamatergic system with neurotransmitters & neurotrophic factors in neurological diseases
- Individual chapters deal with the neuropathophysiology and glutamate-based treatment options of a specific CNS disease
- Presents translational principles used in the development of CNS glutamate-based therapeutic modalities
This volume provides a comprehensive overview of recent advances in targeting glutamate signaling for the treatment of major psychiatric and neurological disorders. It draws on the latest findings in glutamate neurobiology and offers valuable insights into the application of translational principles in neuroscience drug discovery and development.
In each chapter, glutamate as a neurotransmitter, its receptors and transporters, and their interplay with other neurotransmitters and neurotrophic factors, are discussed in the context of a specific, highly prevalent and disabling CNS disease. Most recent and detailed information is provided on Ischemic Stroke, Chronic Stress, Major Depressive Disorder, Bipolar Disorder, Autism Spectrum Disorders (ASD), Posttraumatic Stress Disorder (PTSD), Alzheimer’s Dementia, Schizophrenia, Impulsive Aggression, Substance Use Disorders (SUD), Amyotrophic Lateral Sclerosis (ALS), Chronic Pain, Multiple Sclerosis, Parkinson’s Disease, Attention Deficit Hyperactivity Disorder (ADHD), Migraine, Epilepsy and Anxiety disorders.
Moreover, the book includes an extensive overview of glutamatergic treatments already available on the market, and those which are currently in pharmaceutical drug development pipelines.
The primary beneficiaries will be neurology and psychiatry specialists and residents, neuroscientists, neuropharmacologists, pharmaceutical industry and clinical research organization professionals, academics, and clinicians working with psychiatric and neurological patients with comorbidities such as cardiologists, pulmonologists, and endocrinologists. This book will also appeal to psychiatry and neurology subspecialists and clinicians working in neuroscience labs seeking an easy-to-understand yet comprehensive overview of contemporary evidence-based clinical insights backed by basic science (preclinical) research evidence.
Given its scope, the book is also a unique and indispensable resource for both preclinical and clinical neuroscientists, medical advisors, and clinical research specialists in the pharmaceutical industry. In addition, it will appeal to neuroscience and neuropsychopharmacology students and guide them through the complexities of glutamate involvement in the pathophysiology of the most common debilitating brain diseases with high unmet medical needs.
Table of Contents- Treatments Against Glutamatergic Excitotoxicity in Ischemic Stroke
- Definitions and Concepts of Stress
- Role of Glutamatergic Neurotransmission in the Pathophysiology of Stress-Related Disorders and Chronic Stress Response
- Current Glutamatergic Treatments and Future Directions for Glutamate-Based Management of Chronic Stress and Stress-Related Disorders
- The Role of the Glutamate System in Posttraumatic Stress Disorder and Glutamate-Based Treatments
- Glutamate in Migraine Neurobiology and Treatment
- Astrocyte Glutamate Transporter EAAT2 in Alzheimer Dementia
- The Glutamatergic System as a Target for the Development of New Pharmacological Treatments of Bipolar Disorder
- CNS Glutamate in Impulsive Aggression
- Glutamatergic Treatments for Parkinson’s Disease
- The Modulation of Glutamatergic Signaling as a Potential Therapeutic Strategy for Major Depression
- Glutamate-Based Treatment for Amyotrophic Lateral Sclerosis/Motor Neuron Disease
- Modulation of Glutamate for Chronic Pain Management
- Pharmacological Role of Glutamate Transporters in Substance Use Disorders
- Glutamate in Multiple Sclerosis: From Pathophysiology to Treatments
- The Role of Glutamate Dysregulation in the Etiology of ADHD
- Glutamate, Glutamatergic Drugs and Schizophrenia
- Glutamate and Epilepsy: An Insight from Temporal Lobe Epilepsy
- Glutamate Function in Anxiety Disorders and OCD: Evidence from Clinical and Translational Studies
- Modulators of Glutamatergic Signaling as Potential Treatments for Autism Spectrum Disorders
